SEARCH

SEARCH BY CITATION

References

  • 1
    Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054 60.
  • 2
    Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93 9.
  • 3
    Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831 47.
  • 4
    Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. Antimicrob Agents Chemother 1991; 27(suppl C): 29 40.
  • 5
    Whelton A & Solez K. Aminoglycoside nephrotoxicity—a tale of two transports. J Lab Clin Med 1982; 99: 148 55.
  • 6
    Kourilsky O, Solez K, Morel-Maroger L et al. The pathology of acute renal failure due to interstitial nephritis in man with comments on the role of interstitial inflammation and sex in gentamicin nephrotoxicity. Medicine 1982; 61: 258 68.
  • 7
    Moench TR & Smith CR. Risk factors for aminoglycoside nephrotoxicity. In: WheltonA, NeuHC, eds. The aminoglycosides. New York: Marcel Dekker, Inc., 1982: 401 15.
  • 8
    Whelton A. Aminoglycoside kinetics and clinical use in renal insufficiency. In: WheltonA, NeuHC, eds. The aminoglycosides. New York: Marcel Dekker, Inc., 1982: 585 609.
  • 9
    Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352 7.
  • 10
    Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173 9.
  • 11
    Maller R, Ahrne H, Holmen C, Lausen I, Nilsson LE, the Scandinavian Amikacin Once Daily Study Group. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993; 31: 939 48.
  • 12
    Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections—a randomized clinical trial. J Antimicrob Chemother 1994; 33: 823 35.
  • 13
    Blaser J & Konig C. Once daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029 38.
  • 14
    Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39 43.
  • 15
    Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J 1996; 312: 338 45.
  • 16
    Ferriols-Lisart R & Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharmacol 1996; 53: 1141 50.
  • 17
    Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717 25.
  • 18
    Munckhof WJ, Grayson ML, Tumidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645 63.
  • 19
    Ali MZ & Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796 809.
  • 20
    Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786 95.
  • 21
    Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997; 24: 810 15.
  • 22
    Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13: 735 9.
  • 23
    Koo J, Tight R, Rajkumar V, Hawa Z. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 1996; 101: 177 83.
  • 24
    Peters Volleberg GW, Dortant PM, Speijers GJ. Comparison of tobramycin nephrotoxicity in young adult and aged female rats. Pharmacol Toxicol 1999; 84: 147 53.
  • 25
    Prins JM, Van Weverling GJ, Ketel RJ, Speelman P. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther 1997; 62: 106 11.
  • 26
    Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470 5.
  • 27
    Giuliano RA, Paulus GJ, Verpooten GA et al. Recovery of cortical phospholipidoses and necrosis after acute gentamicin loading in rats. Kidney Int 1984; 26: 838 47.
  • 28
    De Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen: two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986; 80(suppl 6B): 115 18.
  • 29
    Wenk M, Vozeh S, Follath F. Serum level monitoring of antimicrobial drugs. A review. Clin Pharmacokinet 1984; 9: 475 92.
  • 30
    Parker SE & Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31: 4 8.
  • 31
    Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335 9.
  • 32
    Frame PT, Phair JP, Watanakunakorn C, Bannister TWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977; 135: 952 7.
  • 33
    Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978; 4(suppl A): 85 101.
  • 34
    Bennet WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576 80.
  • 35
    Wood CA, Norton DR, Kohlhepp SJ et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13 22.
  • 36
    Giuliano RA, Verpooten GA, De Broe ME. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 1986; 7: 297 303.
  • 37
    De Broe ME, Giuliano RE, Verpooten GA. Insights into the renal handling of aminoglycosides: a guideline for prevention of nephrotoxicity. J Drug Dev 1988; 1(suppl 3): 83 92.
  • 38
    Verpoten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22 7.
  • 39
    Bertino JS & Rotschafer JC. Editorial response: single daily dosing of aminoglycosides—a concept whose time has not yet come. Clin Infect Dis 1997; 24: 820 3.
  • 40
    Cometta A, Zinners S, De Bock R et al. Piperacillin–tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445 52.
  • 41
    Whelton A. Clinical strategies for the reduction of aminoglycoside nephrotoxicity and ototoxicity. Chemotherapia 1984; 3(suppl 5): 52 9.
  • 42
    De Broe ME, Paulus GT, Verpooten GA et al. Early effects of gentamicin, tobramycin and amikacin on the human kidney. Kidney Int 1984; 25: 643 52.
  • 43
    Williams PD, Hottendorf GH, Bennett DB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther 1986; 237: 919 25.
  • 44
    Neuman M. Relationships between chemical structure and adverse effects of antibacterial and antifungal agents. Chemioterapia 1987; 6: 299 305.
  • 45
    Gilbert DN, Lee BL, Dworkin RJ et al. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin–clavulanate. Am J Med 1998; 105: 182 91.DOI: 10.1016/s0002-9343(98)00244-7
  • 46
    Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549 55.
  • 47
    Tange RA, Dreschler WA, Prins JM, Büller HR, Kuijper EJ, Speelman P. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. Clin Otolaryngol 1995; 20: 118 23.
  • 48
    Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650 5.
  • 49
    Nicolau DP, Wu AH, Finocchiaro S et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 1996; 18: 263 6.
  • 50
    Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy 1997; 17: 810 14.
  • 51
    Beaucaire G. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother 1995; 7(suppl 2): 165 73.
  • 52
    Blum D. An overview of the safety of isepamicin in adults. J Chemother 1995; 7(suppl 2): 87 93.
  • 53
    Beauchamp D, Labrecque G, Bergeron MG. Is it still possible to reduce the incidence of nephrotoxicity of aminoglycosides? Pathol Biol 1995; 43: 779 87.
  • 54
    Fabrizii V, Thalhammer F, Hörl WH. Aminoglycoside-induced nephrotoxicity. Wien Klin Wochenschr 1997; 109: 830 5.
  • 55
    Van Lent Evers NA, Mathôt RA, Van Geus WP, Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63 73.